Quote:

---

(1) Is there a reason why TAS-102 and Bevacizumab is being used in conjunction with Leronlimab instead of a checkpoint inhibitor? Is it because TAS-102 and Bevacizumab is the standard of care?

---

yes

Quote:

---

(2) If Leronlimab helps the standard of care and raises the PD-L1 but the treatment fails, can they continue with Leronlimab and add a checkpoint inhibitor like Keytruda (which is approved for colon and rectal cancer treatment) as a second or follow-on treatment?

In Question 2 I'm thinking of a situation where PD-L1 is raised (as measured by Creatv Bio's test) and CTC and CAMLs are reduced but the disease has not entirely been mitigated.

---

I suspect anyone in the mssCRC trial with medium to high expression of PD-L1 will be put on PD-L1 inhibitors regardless of progression or non-progression of disease state.